New pill shows promise against blood cancers in early trial

NCT ID NCT05728658

Recruiting now Disease control Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage study tests an experimental drug called ICP-248, taken as a pill, for people with certain blood cancers (like leukemia or lymphoma). The drug is given alone or with another drug, orelabrutinib. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 191 adults aged 18 to 80 are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ICP-248 (an experimental oral drug) alone or combined with orelabrutinib
What this could lead to: If successful, this could point toward a new treatment option for certain blood cancers like leukemia or lymphoma.
What could go wrong: This is an early Phase 1 trial, so safety and proper dosing are the main focus—not yet proof of effectiveness. Side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lymphoplasmacytic lymphoma mantle cell lymphoma marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Locations

Fujian Medical University Union Hospital
RECRUITING

Fuzhou, Fujian, 350001, China
Hematology Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450008, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410000, China
Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, 210029, China
Jiangxi Cancer Hospital
RECRUITING

Nanchang, Jiangxi, 330029, China
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100191, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China
Shandong cancer hospital
RECRUITING

Jinan, Shandong, 250117, China
Shenyang Hospital Of China Medical University
RECRUITING

Shenyang, Liaoning, 110022, China
Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510062, China
The Central Hospital of Wuhan
RECRUITING

Wuhan, Hubei, 430014, China
The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, Anhui, 230022, China
The First Affiliated Hospital of Bengbu Medical College
RECRUITING

Bengbu, Anhui, 233099, China
The First Affiliated Hospital of Chongqing Medical University
RECRUITING

Chongqing, Chongqing Municipality, 400016, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330000, China
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, 361003, China
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450008, China
The Second Hospital of Dalian Medical University
RECRUITING

Dalian, Liaoning, 116027, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430022, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.